NCT06649656Not yet recruitingPhase 1
A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.1 site in 1 country100 target enrollmentStarted: November 2024Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Adverse events (AE) rate
Study Overview
Brief Summary
This study is a multicenter, single arm, and open design Phase I clinical trial aimed at evaluating the safety, Pharmacokinetics (PK) characteristics, immunogenicity, and preliminary efficacy of TQB2252 injection in subjects with advanced malignant tumors.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •The subjects voluntarily joined this study, signed an informed consent form, and showed good compliance;
- •18 years old ≤ 75 years old (calculated from the date of signing the informed consent form);
- •Electrocorticogram (ECOG) score ranges from 0 to 1 points;
- •Expected survival is greater than 12 weeks；
- •Confirmed to have at least one measurable lesion according to RECIST 1.1 (solid tumor) or Lugano 2014 (lymphoma) criteria；
- •Late stage malignant tumor subjects who have failed standard treatment or lack effective treatment；
- •Women of childbearing age should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study; Men should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study period.
Exclusion Criteria
- •Has experienced or currently has other malignant tumors within the past 5 years prior to the first use of medication;
- •There are multiple factors that affect diseases related to intravenous injection and venous blood collection;
- •The adverse reactions of previous anti-tumor treatments have not recovered to a Common Terminology Criteria for Adverse Events (CTCAE) v5.0 score of ≤ 1;
- •Individuals who have undergone major surgical treatment, significant traumatic injury, or are expected to undergo major surgery during the expected study treatment period within 4 weeks prior to the first use of medication;
- •Subjects who experience any bleeding or bleeding events ≥ CTCAE grade 3 within 4 weeks prior to the first administration;
- •An arterial/venous thrombotic event occurred within 6 months prior to the first administration;
- •Active viral hepatitis with poor control;
- •Active syphilis infected individuals in need of treatment;
- •History of active pulmonary tuberculosis, idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radiation pneumonitis requiring treatment, or clinically symptomatic active pneumonia;
- •Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders;
- •Diagnosed with immunodeficiency or undergoing systemic glucocorticoid therapy or any other form of immunosuppressive therapy due to a history of hepatic encephalopathy;
- •Previously experienced grade 3 or higher adverse reactions related to immunotherapy;
- •Suffering from significant cardiovascular disease;
- •Active or uncontrolled severe infections;
- •Patients with renal failure requiring hemodialysis or peritoneal dialysis;
- •History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases;
- •Individuals with epilepsy who require treatment;
- •Previously received treatment with similar anti-lag3 drugs.
Arms & Interventions
TQB2252 injection
Experimental
This product is administered via intravenous infusion, with recommended doses of 600mg TQB2223 monoclonal antibody and 200mg penpulimab injection, administered once every 3 weeks.
Intervention: TQB2252 injection (Drug)
Outcomes
Primary Outcomes
Adverse events (AE) rate
Time Frame: From date of the first dose until the date of 28 days after last dose or new anti-tumor treatment, whichever came first.
The evaluation criteria for the nature and severity of adverse events are based on the National Cancer Institute's CommonTerminology Criteria for Adverse Events (NCI CTCAE version 5.0).
Secondary Outcomes
- Progression-free survival (PFS)(up to 2 years)
- Time to reach maximum observed plasma concentration (Tmax)(Day1 of Cycle1, Cycle3: within 30 minutes pre-dose, 0.25, 2, 4, 8, 24, 48, 168, 336 hour post dose. Day1 of Cycle2, Cycle4～Cycle 8: pre-dose. (Each cycle is 21 days))
- Maximum Plasma Concentration (Cmax)(Day1 of Cycle1, Cycle3: within 30 minutes pre-dose, 0.25, 2, 4, 8, 24, 48, 168, 336 hour post dose. Day1 of Cycle2, Cycle4～Cycle 8: pre-dose. (Each cycle is 21 days))
- Elimination half-life (t1/2)(Day1 of Cycle1, Cycle3: within 30 minutes pre-dose, 0.25, 2, 4, 8, 24, 48, 168, 336 hour post dose. Day1 of Cycle2, Cycle4～Cycle 8: pre-dose. (Each cycle is 21 days))
- Objective Response Rate (ORR)(up to 2 years)
- Disease control rate (DCR)(up to 2 years)
- Duration of Response (DOR)(up to 2 years)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.Β-thalassemiaNCT06655662Shenzhen Hemogen8
Recruiting
Phase 1
Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes MellitusDiabetes MellitusDiabetes Mellitus, Type 1NCT06731218Hangzhou Reprogenix Bioscience, Inc10
Terminated
Phase 1
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With MelanomaUnresectable, Recurrent or Metastatic MelanomaUntreated Mucosal or Acral Lentiginous MelanomaNCT04653038Zai Lab (Shanghai) Co., Ltd.92
Recruiting
Phase 1
A Phase I Study of NK042 Cell Injection in Advanced Solid TumorsAdvanced Solid TumorsNCT06773091Shanghai NK Cell Technology Co., LTD76
Recruiting
Phase 1
Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV InfectionEBV-associated Hemophagocytic LymphohistiocytosisEBV InfectionNCT06135922Chinese PLA General Hospital9